Abstract
Background:
We have investigated β3-adrenoceptor agonist mediated brown adipose tissue (BAT) activation using (18)F-FDG PET/CT in Zucker lean (ZL) and obese (ZF) rats.
Methods:
(18)F-FDG was injected into ZL and ZF rats pretreated with saline or agonist CL316,243 for scans. (18)F-FDG metabolic activity was computed as standard uptake values.
Results:
CL316,243 in ZL activated BAT up to 4-fold compared to saline, while ZF BAT was only up by 2 fold. The decreased activation was consistent with lower β3-adrenoceptor levels in ZF rats.
Conclusions:
The genetically modified ZL and ZF rats may provide a useful rat model to evaluate the significance of β3-adrenoceptor agonist-induced BAT activation in obesity.
Keywords:
(18)F-FDG; CL316,243; Obesity; PET/CT; β3-Adrenoceptor agonist.
Copyright © 2015 Elsevier Inc. All rights reserved.
Publication types
-
Comparative Study
-
Evaluation Study
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adipose Tissue, Brown / diagnostic imaging*
-
Adipose Tissue, Brown / metabolism*
-
Adrenergic beta-3 Receptor Agonists / pharmacology*
-
Animals
-
Dioxoles / pharmacology*
-
Fluorine Radioisotopes / pharmacokinetics
-
Fluorodeoxyglucose F18 / pharmacokinetics*
-
Isotope Labeling
-
Male
-
Metabolic Clearance Rate
-
Obesity / genetics
-
Positron-Emission Tomography / methods*
-
Radiopharmaceuticals / pharmacokinetics*
-
Rats
-
Rats, Zucker
-
Receptors, Adrenergic, beta-3 / metabolism
-
Thinness / genetics
-
Tissue Distribution
Substances
-
Adrenergic beta-3 Receptor Agonists
-
Dioxoles
-
Fluorine Radioisotopes
-
Radiopharmaceuticals
-
Receptors, Adrenergic, beta-3
-
Fluorodeoxyglucose F18
-
disodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate